Subtype
Glioblastoma
CI-CAN-00000934GBMExplore in graph →
486 active trials2 approved drugs43 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000934GBMExplore in graph →
Clinical trials
1,750 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (282)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04614909 | Study of Pamiparib in Newly Diagnosed and rGBM | completed | Early Phase 1 | 50 | Nader SanaiOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04391595 | LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients | completed | Early Phase 1 | 42 | Nader SanaiOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05432375 |
| completed |
| Early Phase 1 |
| 10 |
| Mundipharma Research LimitedINDUSTRY |
| 2 |
| Dec 10, 2025 |
| clinicaltrials |
| NCT01165632 | Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma | completed | Early Phase 1 | 24 | Mayo ClinicOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT03834740 | A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection | completed | Early Phase 1 | 27 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT03477110 | Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma | completed | Early Phase 1 | 30 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03995706 | Neuro/Sacituzumab Govitecan/Breast Brain Metastasis/Glioblastoma/Ph 0 | completed | Early Phase 1 | 26 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT05977738 | Repurposed Drugs in Research for Cancer Clinical Trials- Pitavastatin(ReDiReCCT-Pita) | completed | Early Phase 1 | 12 | C.DirvenOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT04937413 | The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation | completed | Early Phase 1 | 32 | Duke UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03454295 | Easing Psychosocial Burden for Informal Caregivers | completed | Early Phase 1 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT01383135 | Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2 | completed | Early Phase 1 | 27 | Stanford UniversityOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT01957956 | Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | completed | Early Phase 1 | 21 | Mayo ClinicOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT03360708 | Vaccine Therapy in Treating Patients With Recurrent Glioblastoma | completed | Early Phase 1 | 20 | Mayo ClinicOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT03020017 | NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery | completed | Early Phase 1 | 8 | Northwestern UniversityOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT02885272 | FDG PET Imaging in Diagnosing Patients With Glioblastoma | completed | Early Phase 1 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 21, 2022 | clinicaltrials |
| NCT03291990 | 5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme | completed | Early Phase 1 | 3 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Nov 19, 2021 | clinicaltrials |
| NCT02630030 | Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma | completed | Early Phase 1 | 3 | Emory UniversityOTHER | 1 | Mar 26, 2021 | clinicaltrials |
| NCT02605746 | Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis | completed | Early Phase 1 | 10 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Dec 11, 2020 | clinicaltrials |
| NCT02207010 | A Phase 0 Study of AZD1775 in Recurrent GBM Patients | completed | Early Phase 1 | 20 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT02768389 | Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma | completed | Early Phase 1 | 18 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 15, 2019 | clinicaltrials |
| NCT01907165 | Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide | completed | Early Phase 1 | 21 | Washington University School of MedicineOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT01091792 | Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM) | completed | Early Phase 1 | 13 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 25, 2018 | clinicaltrials |
| NCT02466828 | qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia. | completed | Early Phase 1 | 10 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01867593 | MET-PET for Newly Diagnosed Glioblastoma | completed | Early Phase 1 | 20 | Massachusetts General HospitalOTHER | 1 | Oct 13, 2017 | clinicaltrials |
| NCT02490930 | A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma | completed | Early Phase 1 | 5 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 13, 2017 | clinicaltrials |
| NCT00864864 | Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma | completed | Early Phase 1 | 8 | Massachusetts General HospitalOTHER | 1 | Jul 7, 2016 | clinicaltrials |
Data updated 22 days agoSource updated May 14, 2026source: clinicaltrials